77,607 Shares in Tourmaline Bio, Inc. $TRML Bought by Nuveen LLC

Nuveen LLC bought a new stake in Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 77,607 shares of the company's stock, valued at approximately $1,180,000. Nuveen LLC owned about 0.30% of Tourmaline Bio at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in TRML. Invesco Ltd. grew its stake in Tourmaline Bio by 10.8% during the 4th quarter. Invesco Ltd. now owns 12,155 shares of the company's stock worth $247,000 after purchasing an additional 1,181 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Tourmaline Bio by 297.6% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,646 shares of the company's stock valued at $33,000 after acquiring an additional 1,232 shares during the last quarter. SG Americas Securities LLC boosted its stake in Tourmaline Bio by 3.9% in the first quarter. SG Americas Securities LLC now owns 36,180 shares of the company's stock valued at $550,000 after acquiring an additional 1,368 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Tourmaline Bio by 12.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,378 shares of the company's stock valued at $291,000 after acquiring an additional 1,598 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Tourmaline Bio by 2.8% during the first quarter. Charles Schwab Investment Management Inc. now owns 65,850 shares of the company's stock worth $1,002,000 after purchasing an additional 1,791 shares during the last quarter. 91.89% of the stock is currently owned by institutional investors and hedge funds.

Tourmaline Bio Price Performance

NASDAQ TRML traded down $0.01 on Thursday, hitting $25.10. 341,324 shares of the company were exchanged, compared to its average volume of 281,290. The firm has a market capitalization of $644.82 million, a P/E ratio of -7.32 and a beta of 2.04. The company's 50 day moving average price is $20.38 and its 200-day moving average price is $17.31. Tourmaline Bio, Inc. has a twelve month low of $11.56 and a twelve month high of $29.79.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.04. As a group, equities analysts expect that Tourmaline Bio, Inc. will post -3.02 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on TRML. Chardan Capital restated a "buy" rating and set a $70.00 target price on shares of Tourmaline Bio in a report on Thursday, August 14th. Guggenheim reiterated a "buy" rating and set a $55.00 target price on shares of Tourmaline Bio in a report on Thursday, August 14th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus price target of $50.14.

Tourmaline Bio Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.